Combination of Acimtamig and AlloNK Effective in R/R Classical Hodgkin Lymphoma
Acimtamig combined with AlloNK demonstrated high objective response rates, including 100% ORR in the DL2+300 mg cohort, in heavily pretreated relapsed/refractory classical Hodgkin lymphoma patients.
Phase 2, open‑label LuminICE‑203 study assessed the efficacy of Acimtamig with AlloNK in 24 heavily pretreated R/R classical Hodgkin lymphoma patients; overall ORR was 87.5% with 14 complete responses. The DL2 + 300 mg cohort achieved 100% ORR. Six‑month progression‑free survival was 61%, and safety was manageable with mostly mild infusion‑related reactions and cytokine‑release syndrome.
These data suggest a potentially efficacious treatment for heavily pretreated HL patients with limited options, showing durable responses and a favorable safety profile in an early‑phase trial.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.
- Overcoming PD‑1 Resistance in Relapsed/Refractory Hodgkin Lymphoma
- Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
- Working towards harmonization of clinical trial reporting in Hodgkin lymphoma
- Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies